drugset / Trial / NCT01151904

Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients

NCT01151904

Phase 4 Terminated 17 enrolled Allergan
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety and efficacy of patients switched from latanoprost monotherapy to a combination therapy of latanoprost with COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) for chronic angle closure glaucoma.

Timeline

Start
2009-11
Primary completion
2012-02
Completion
2012-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule 0.2 % Other
Subject Timolol Other / unclassified 0.5 % Other
Background Latanoprost Small molecule Other